More recently, mammalian target of rapamycin (mTOR) inhibitors such as sirolimus have shown promising results in reducing rates of cellular proliferation of AMLs in patients with TSC, as these patients are often found to have upregulation of mTOR in tumor cell lines [34]. This evidence concerns the gene MTOR and neoplasm.